Djdbsl//@HelenJanet:Large cap healthcare stocks remain an attractive defensive stock during market uncertainty. It has benefited from widespread concerns about an economic downturn. Even in a recession, consumers will still need to seek out health services. I like $Johnson & Johnson(JNJ)$ as it is the biggest pharmaceutical company in the world by revenue and it is considered by many to be a safe stock. It is also a trusted brand of baby products which I have used for my children when they were young. Dividend is paid quarterly and the dividend yield is 2.47%. It has increased its payouts annually for 60 consecutive years. 2022 dividend was as follow Feb 22 - USD 1.06 May 22 - USD 1.13 Aug 22 - USD 1.13 Nov 22 - USD 1.13 2021 dividend was as follow: Feb 21 - USD 1.01 May 21 - USD 1.06 Aug 21 - USD 1.06 Nov 21 - USD 1.06 As of December 2022, Johnson & Johnson has a market capitalisation of USD 464.02 billion. This makes Johnson & Johnson the world's 8th most valuable company by market capitalisation. (The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.) The company has a diverse revenue stream with several divisions posting outsized growth, and it's making moves to maintain that growth over the next few years. This healthcare conglomerate's business is fairly diverse, generating billions in revenue from its consumer health, pharmaceutical, and medtech businesses. Its pharmaceutical segment is far and away its largest revenue generator, representing more than half of the company's overall sales. For the third quarter (which ended Sept. 30), pharmaceutical revenue totalled $13.2 billion, accounting for 56% of the $23.8 billion in total sales. The pharma segment's Q3 sales grew a modest 2.6% year over year. Its top-selling drugs were psoriasis medication Stelara and cancer treatment Darzalex, which each managed more than $2 billion in quarterly sales. On 12 Dec 22, Citi analyst kept a “BUY” rating on Johnson & Johnson stock and raised the price target to $205 from $198. Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields.